Literature DB >> 18669447

Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.

Eleni Andreopoulou, Gabriel N Hortobagyi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18669447     DOI： 10.1200/JCO.2008.16.1026

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

1.  Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Authors:  Federica Cuppone; Emilio Bria; Vanja Vaccaro; Fabio Puglisi; Alessandra Fabi; Isabella Sperduti; Paolo Carlini; Michele Milella; Cecilia Nisticò; Michelangelo Russillo; Paola Papaldo; Gianluigi Ferretti; Matti Aapro; Diana Giannarelli; Francesco Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2011-05-12

2.  Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.

Authors:  Leonardo Tenori; Catherine Oakman; Wederson M Claudino; Patrizia Bernini; Silvia Cappadona; Stefano Nepi; Laura Biganzoli; Michael C Arbushites; Claudio Luchinat; Ivano Bertini; Angelo Di Leo
Journal:  Mol Oncol       Date:  2012-06-01       Impact factor: 6.603

3.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

4.  Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery.

Authors:  Marta Kijanka; Frank-Jan Warnders; Mohamed El Khattabi; Marjolijn Lub-de Hooge; Gooitzen M van Dam; Vasilis Ntziachristos; Liesbeth de Vries; Sabrina Oliveira; Paul M P van Bergen En Henegouwen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-19       Impact factor: 9.236

5.  Kallikrein 11 Down-regulation in Breast Carcinoma: Correlation With Prognostic Parameters.

Authors:  Tulin Ozturk; Ecem Zeynep Kain; Mete Bora Tuzuner; Ayca Diren; Sebnem Batur; Hulya Yilmaz-Aydogan; Oguz Ozturk; Turgay Isbir
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 6.  International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

Authors:  Olivia Pagani; Elzbieta Senkus; William Wood; Marco Colleoni; Tanja Cufer; Stella Kyriakides; Alberto Costa; Eric P Winer; Fatima Cardoso
Journal:  J Natl Cancer Inst       Date:  2010-03-10       Impact factor: 13.506

7.  Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.

Authors:  Mario Giuliano; Antonio Giordano; Summer Jackson; Kenneth R Hess; Ugo De Giorgi; Michal Mego; Beverly C Handy; Naoto T Ueno; Ricardo H Alvarez; Michelino De Laurentiis; Sabino De Placido; Vicente Valero; Gabriel N Hortobagyi; James M Reuben; Massimo Cristofanilli
Journal:  Breast Cancer Res       Date:  2011-06-15       Impact factor: 6.466

8.  NT5E CpG island methylation is a favourable breast cancer biomarker.

Authors:  C Lo Nigro; M Monteverde; S Lee; L Lattanzio; D Vivenza; A Comino; N Syed; A McHugh; H Wang; C Proby; O Garrone; M Merlano; E Hatzimichael; E Briasoulis; O Gojis; C Palmieri; L Jordan; P Quinlan; A Thompson; T Crook
Journal:  Br J Cancer       Date:  2012-05-31       Impact factor: 7.640

9.  Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message?

Authors:  Su Yon Jung; Margaret Rosenzweig
Journal:  Front Public Health       Date:  2013-11-11

10.  Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.

Authors:  Emman Shubbar; Anikó Kovács; Shahin Hajizadeh; Toshima Z Parris; Szilárd Nemes; Katrin Gunnarsdóttir; Zakaria Einbeigi; Per Karlsson; Khalil Helou
Journal:  BMC Cancer       Date:  2013-01-02       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.